What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?

Cell Reports Medicine
Jens J Holst

Abstract

Lu et al.1 previously demonstrated that antagonist antibodies against the GIP receptor promote weight loss combined with GLP-1. They now elegantly developed a conjugate of GIPR antibodies and GLP-1 and show effective weight loss in obese non-human primates.

References

Nov 1, 2013·Science Translational Medicine·Brian FinanMatthias H Tschöp
Dec 21, 2018·Science Translational Medicine·Elizabeth A KillionDavid J Lloyd
Nov 27, 2019·Molecular Metabolism·T D MüllerM H Tschöp
May 28, 2020·The Journal of Clinical Endocrinology and Metabolism·Jens Juul Holst, Mette Marie Rosenkilde
Jul 31, 2020·JCI Insight·Francis S WillardKyle W Sloop
Feb 11, 2021·The New England Journal of Medicine·John P H WildingUNKNOWN STEP 1 Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Biochemical and Biophysical Research Communications
Cherl NamKoongHyung Jin Choi
Journal of Diabetes Investigation
Yuichiro YamadaTakuma Narita
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme
Jens J Holst
© 2021 Meta ULC. All rights reserved